Clinical Trial: Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior Chemotherapy

U.S., June 11 -- ClinicalTrials.gov registry received information related to the study (NCT07639086) titled 'Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior Chemotherapy' on June 05.

Brief Summary: This is a phase 2, open-label, single-arm study of sacituzumab tirumotecan in neuroendocrine prostate cancer (NEPC) with progression after platinum-based chemotherapy.

Study Start Date: Aug. 31

Study Type: INTERVENTIONAL

Condition: Prostate Cancer Neuroendocrine Prostate Cancer (NEPC)

Intervention: DRUG: Sacituzumab Tirumotecan

Sacituzumab tirumotecan will be administered by intravenous (IV) infusion on Days 1, 15, and 29 of each 42-day cycle until disease progression or criteria of disease progression met

Recruitment S...